Laparoscopic Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer in CDH1 Mutation Carriers
- PMID: 34097461
- DOI: 10.1089/lap.2021.0239
Laparoscopic Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer in CDH1 Mutation Carriers
Abstract
Background: Patients with hereditary diffuse gastric cancer (HDGC) and germline mutations in the E-cadherin gene, CDH1, have a very high cumulative lifetime risk of developing diffuse gastric cancer. In these patients, it is formally recommended to perform a prophylactic total gastrectomy (PTG). Materials and Methods: We analyzed the course of patients with HDGC who have undergone PTG in our institution. Pedigree analysis, preoperative screening results, operative course, postoperative data, and complete stomach pathologic examination were performed in all patients. Results: Seven patients with confirmed CDH1 mutation underwent PTG, five were women, and average age was 27 years (range 17-42). Signet ring cell carcinoma was found in 1 patient in the preoperative surveillance endoscopic biopsies. Laparoscopic PTG was performed in all patients. There were two complications, an intestinal obstruction that required reintervention and an asymptomatic esophagojejunal anastomosis leak that resolved with conservative treatment. In all gastrectomy specimens, intramucosal signet ring cell carcinoma foci limited to the lamina propria were found (range 1-31), 83.5% were in the body-fundus region. The mean follow-up was 28.5 months (range 8-72). The mean weight loss was 9% (range 2-18). Postoperative symptoms associated with Dumping syndrome were the most frequent. All the patients reported of being very satisfied with the procedure and of having a better quality of life than expected before the procedure. Conclusion: Laparoscopic PTG is an excellent resource to prevent the development of advanced diffuse gastric cancer (DGC) in patients with HDGC with CDH1 mutation. The procedure was well tolerated with a high satisfaction rate and very good functional results. It should be considered in these patients due to the high risk of developing advanced DGC and the lack of effective and reliable surveillance studies.
Keywords: CDH1; hereditary diffuse gastric cancer; laparoscopy; prophylactic total gastrectomy.
Similar articles
-
Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients.Ann Surg Oncol. 2009 Jul;16(7):1890-5. doi: 10.1245/s10434-009-0471-z. Epub 2009 May 1. Ann Surg Oncol. 2009. PMID: 19408054
-
Laparoscopic prophylactic total gastrectomy with limited lymphadenectomy for CDH1 gene carriers.Surg Endosc. 2023 Dec;37(12):9373-9380. doi: 10.1007/s00464-023-10303-7. Epub 2023 Aug 29. Surg Endosc. 2023. PMID: 37644154
-
Total Gastrectomy for CDH-1 Mutation Carriers: An Institutional Experience.J Surg Res. 2020 Mar;247:438-444. doi: 10.1016/j.jss.2019.09.062. Epub 2019 Nov 1. J Surg Res. 2020. PMID: 31685251
-
CDH1 and hereditary diffuse gastric cancer: a narrative review.Chin Clin Oncol. 2023 Jun;12(3):25. doi: 10.21037/cco-23-36. Epub 2023 Jun 5. Chin Clin Oncol. 2023. PMID: 37303221 Review.
-
The role of endoscopy in the management of hereditary diffuse gastric cancer syndrome.World J Gastroenterol. 2019 Jun 21;25(23):2878-2886. doi: 10.3748/wjg.v25.i23.2878. World J Gastroenterol. 2019. PMID: 31249446 Free PMC article. Review.
Cited by
-
Pioneering use of genetic analysis for CDH1 to identify candidates for prophylactic total gastrectomy to prevent hereditary diffuse gastric cancer.eGastroenterology. 2023 Sep;1(2):e100017. doi: 10.1136/egastro-2023-100017. Epub 2023 Dec 9. eGastroenterology. 2023. PMID: 38188186 Free PMC article.
-
Early stage gastric adenocarcinoma: clinical and molecular landscapes.Nat Rev Clin Oncol. 2023 Jul;20(7):453-469. doi: 10.1038/s41571-023-00767-w. Epub 2023 Jun 1. Nat Rev Clin Oncol. 2023. PMID: 37264184 Free PMC article. Review.
-
Current advances and challenges in Managing Hereditary Diffuse Gastric Cancer (HDGC): a narrative review.Hered Cancer Clin Pract. 2024 Oct 8;22(1):21. doi: 10.1186/s13053-024-00293-5. Hered Cancer Clin Pract. 2024. PMID: 39379994 Free PMC article. Review.
-
An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma.J Healthc Eng. 2022 Apr 25;2022:3035073. doi: 10.1155/2022/3035073. eCollection 2022. J Healthc Eng. 2022. PMID: 35509706 Free PMC article.
-
CDH1 mutations recurrence and global clustering in genetically tested families with hereditary diffuse gastric cancer syndrome: results from a systematic study.Fam Cancer. 2023 Apr;22(2):187-192. doi: 10.1007/s10689-022-00309-w. Epub 2022 Jul 27. Fam Cancer. 2023. PMID: 35882702
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous